Registreer u om meldingen in te stellen voor instrumenten, economische gebeurtenissen en artikelen van de auteurs die u volgt.
Gratis registreren Heeft u al een account? Inloggen
Noteringen
Alle soorten instrumenten
- Alle soorten instrumenten
- Indexen
- Aandelen
- ETF's
- Fondsen
- Grondst.
- Valuta's
- Crypto
- Obligaties
- Certificaten
Probeer een andere zoekopdracht
Toegang tot premium-data: tot 50% korting InvestingPro BENUT DE SALE
Ubs (lux) Equity Fund - Biotech (usd) Q-acc (0P0000XHD3)
Toevoegen/Verwijderen van een Portfolio
Voeg toe aan Portfolio
328,670
+11,320
+3,57%
Type:
Fonds
Markt:
Luxemburg
Emittent:
UBS Fund Management (Luxembourg) S.A.
ISIN:
LU0400035332
Activaklasse:
Aandeel
- Beoordeling Morningstar:
- Totale activa: 498,51M
UBS Lux Equity Fund - Biotech USD Q-acc
328,670
+11,320
+3,57%
- Overzicht
- Profiel
- Historische Data
- Participaties
0P0000XHD3 Overzicht
Op deze pagina vindt u een uitgebreid profiel van Ubs (lux) Equity Fund - Biotech (usd) Q-acc. Kom meer te weten over onder meer het senior management, de totale activa, de investeringsstrategie en de contactgegevens van 0P0000XHD3.
Contact Informatie
Adres
33A, avenue J.-F. Kennedy, L-1855 Luxembourg
Luxembourg, L-1855
Luxembourg
Luxembourg, L-1855
Luxembourg
Telefoon
+352-441 0101
Topmanagers
| Naam | Titel | Sinds | Tot |
|---|---|---|---|
| Sara Cotter | - | 2022 | now |
| Matthew Konosky | - | 2017 | now |
| Biografie | Matthew Konosky is the Lead Healthcare Portfolio Manager and a Senior Investment Analyst on UBS Asset Management's US Intrinsic Value Equity Team. In his portfolio manager role, Matthew is Lead Portfolio Manager for the Global Healthcare Lux Fund as well as Deputy Portfolio Manager for the Global Biotech Lux Fund. Analyst responsibilities include fundamental company and industry-level research and development of company earnings models for the global pharmaceuticals and health care services sectors. Prior to joining the firm in 2006, Matthew worked as health care services analyst at Sanford C. Bernstein in New York and as a senior consultant at Mars & Co. serving several Fortune 500 health care clients. Matthew has also served as a member of the MIT Educational Counsel since 1997. | ||
| Florian Töpfl | - | 2019 | 2023 |
| Nathalie Lötscher Petrus | - | 2006 | 2022 |
| Christian Suter | - | 2012 | 2019 |
| Biografie | Christian Suter is an Equity Specialist, based in Zurich. He works closely together with the equity investment teams of UBS Asset Management and is responsible for presenting equity strategies to clients, prospects and consultants, primarily focusing on our Swiss, Biotech and Healthcare strategies. Further Christian is the deputy portfolio manager for the Swiss High Dividend and Swiss Income strategies and acts as a member of the portfolio construction team for Swiss Equities. In addition Christian covers Swiss Small and Mid Cap Industrials as well as the Biotech sector as an analyst. In 2009, Christian joined UBS within the graduate training program for the second time, after he made his first experiences at UBS before University in UBS WM&SB and UBS Investment Bank. | ||
| André Leue | - | 2016 | 2017 |
| Biografie | André Leue is a Senior Investment Analyst. He is responsible for industry and company research, qualitative assessment and quantitative financial modelling within the Healthcare sector. André is Deputy Portfolio Manager for the UBS (Lux) Equity Fund – Biotech. André joined UBS Asset Management in February 2010. Prior to this he was head of the Healthcare team at DEKA Investment. As the Lead Portfolio Manager he was responsible for a Healthcare fund and a Biotech fund with combined assets under management of around USD 2bn. Other previous roles included senior financial analyst at Sal. Oppenheim Jr. & Cie and financial auditor at KPMG International. | ||
| Scott Wilkin | - | 2016 | 2016 |
| Biografie | Scott is the Head of the Global Intrinsic Value Equity team and co-PM for our Global equity portfolios. He is also Director of Research (DOR); responsible for managing the 13-member analyst team and driving research quality standards across the Global Intrinsic Value platform. In 2012, Scott was promoted to the position of DOR for the US Intrinsic Value equity team. In this role, Scott managed a team of six sector-based analysts and lead company and industry-level research. Scott was also the lead portfolio manager of the Intrinsic Value equity team's Global Healthcare and UBS Healthcare Long/Short strategies. Prior to being named DOR and portfolio manager, Scott was a Senior Investment Analyst and Sector Head for the health care analyst team. His responsibilities included fundamental company and industry-level research. | ||
| Sara Cotter | - | 2015 | 2016 |
| Angus Muirhead | - | 2012 | 2015 |
Laat weten wat u vindt van Ubs (lux) Equity Fund - Biotech (usd) Q-acc
Weet u zeker dat u deze grafiek wilt verwijderen?
Verwijderen Annuleren
Vervang de toegevoegde grafiek met een nieuwe grafiek?
Vervang Annuleren
Richtlijnen voor commentaar
Voeg Grafiek toe aan Commentaar
Blokkering bevestigen
Weet u zeker dat u %USER_NAME% wilt blokkeren?
Als u dit doet, kunnen u en %USER_NAME% geen publicaties meer van elkaar zien op Investing.com.
%USER_NAME% is toegevoegd aan uw lijst met geblokkeerde personen
Omdat u de blokkering van deze persoon net hebt opgeheven, moet u 48 uur wachten om hem/haar weer te kunnen blokkeren.
Rapporteer dit commentaar
Ik vind dit commentaar
Commentaar gemarkeerd
Bedankt!
Uw bericht is ter beoordeling verstuurd naar de moderatoren